{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-000716","form_type":"8-K","ticker":"SBFM","cik":"0001402328","company_name":"Sunshine Biopharma Inc.","filed_at":"2023-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.768386+00:00","generated_at":"2026-06-19T17:48:23.662425+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Sunshine Biopharma signs research agreement with Jewish General Hospital for Adva-27a anticancer compound","bullets":["3-year agreement to advance Adva-27a through IND-enabling studies; JGH paid fair market value for services.","Sunshine retains exclusive ownership of all improvements and research results; JGH receives 3% royalty for 20 years on net revenues from IP.","Research led by Dr. Gerald Batist, Head of Oncology at JGH and Director of the McGill Centre for Translational Research in Cancer.","If results are conclusive, parties will negotiate terms to conduct a Phase I clinical trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-000716","json":"https://secwatch.observer/filing/0001683168-23-000716.json","markdown":"https://secwatch.observer/filing/0001683168-23-000716.md","text":"https://secwatch.observer/filing/0001683168-23-000716.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823000716/0001683168-23-000716-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823000716/sunshine_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T17:48:23.662425+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e338c40f38eb3fef3ba9fa854279f8f02edeea45","claim":"Sunshine Biopharma Inc. entered into Research Agreement with Sir Mortimer B. Davis Jewish General Hospital valued at 3% royalty (effective 2023-02-07).","evidence_excerpt":"On February 7, 2023, Sunshine Biopharma, Inc. (the “Company”) received a duly executed research agreement (the “Research Agreement”) with Sir Mortimer B. Davis Jewish General Hospital, a McGill University Health Center hospital located in Montreal, Quebec, Canada (“JGH”) in connection with the Company’s Adva-27a anticancer compound.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823000716/0001683168-23-000716-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Sir Mortimer B. Davis Jewish General Hospital"},{"label":"Value","value":"3% royalty"},{"label":"Effective","value":"2023-02-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}